fluoroethyl-L tyrosine (18F)
Phase 2Radiopharmaceutical
fluoroethyl-L tyrosine (18F) is one of 13 small molecule programs targeting Adenoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Adenoma
#DrugCompanyPhaseTrials
1Dostinex
PfizerApproved
Nolvadex
AstraZenecaApproved
Orilissa
AbbVieApproved
Duragesic
CCephalon
Approved
Biaxin
AbbViePreclinical
Avandia
Jazz PharmaceuticalsPreclinical
Ultram
WWim Janssens
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
fluoroethyl-L tyrosine (18F)
UUniversity Hospital, Lille
Phase 2
Drug Treatment
BBiosense Webster, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Lille